540 related articles for article (PubMed ID: 18355388)
1. Add-on omalizumab improves day-to-day symptoms in inadequately controlled severe persistent allergic asthma.
Humbert M; Berger W; Rapatz G; Turk F
Allergy; 2008 May; 63(5):592-6. PubMed ID: 18355388
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G
Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
[TBL] [Abstract][Full Text] [Related]
3. Improvement in quality of life with omalizumab in patients with severe allergic asthma.
Chipps B; Buhl R; Beeh KM; Fox H; Thomas K; Reisner C
Curr Med Res Opin; 2006 Nov; 22(11):2201-8. PubMed ID: 17076981
[TBL] [Abstract][Full Text] [Related]
4. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K
Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
Vignola AM; Humbert M; Bousquet J; Boulet LP; Hedgecock S; Blogg M; Fox H; Surrey K
Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757
[TBL] [Abstract][Full Text] [Related]
6. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM;
J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma.
Ohta K; Miyamoto T; Amagasaki T; Yamamoto M;
Respirology; 2009 Nov; 14(8):1156-65. PubMed ID: 19909462
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality.
Holgate S; Bousquet J; Wenzel S; Fox H; Liu J; Castellsague J
Curr Med Res Opin; 2001; 17(4):233-40. PubMed ID: 11922396
[TBL] [Abstract][Full Text] [Related]
9. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations.
Slavin RG; Ferioli C; Tannenbaum SJ; Martin C; Blogg M; Lowe PJ
J Allergy Clin Immunol; 2009 Jan; 123(1):107-113.e3. PubMed ID: 19130931
[TBL] [Abstract][Full Text] [Related]
10. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany.
Korn S; Thielen A; Seyfried S; Taube C; Kornmann O; Buhl R
Respir Med; 2009 Nov; 103(11):1725-31. PubMed ID: 19515548
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.
Ayres JG; Higgins B; Chilvers ER; Ayre G; Blogg M; Fox H
Allergy; 2004 Jul; 59(7):701-8. PubMed ID: 15180756
[TBL] [Abstract][Full Text] [Related]
12. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma.
Bousquet J; Cabrera P; Berkman N; Buhl R; Holgate S; Wenzel S; Fox H; Hedgecock S; Blogg M; Cioppa GD
Allergy; 2005 Mar; 60(3):302-8. PubMed ID: 15679714
[TBL] [Abstract][Full Text] [Related]
13. Adding omalizumab to the therapy of adolescents with persistent uncontrolled moderate--severe allergic asthma.
Massanari M; Milgrom H; Pollard S; Maykut RJ; Kianifard F; Fowler-Taylor A; Geba GP; Zeldin RK
Clin Pediatr (Phila); 2009 Oct; 48(8):859-65. PubMed ID: 19564449
[TBL] [Abstract][Full Text] [Related]
14. Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis.
Busse WW; Massanari M; Kianifard F; Geba GP
Curr Med Res Opin; 2007 Oct; 23(10):2379-86. PubMed ID: 17711616
[TBL] [Abstract][Full Text] [Related]
15. Relationship between pretreatment specific IgE and the response to omalizumab therapy.
Wahn U; Martin C; Freeman P; Blogg M; Jimenez P
Allergy; 2009 Dec; 64(12):1780-7. PubMed ID: 19627273
[TBL] [Abstract][Full Text] [Related]
16. Omalizumab as add-on therapy to inhaled steroids for asthma.
Hadj Tahar A
Issues Emerg Health Technol; 2004 Jun; (58):1-4. PubMed ID: 15455487
[TBL] [Abstract][Full Text] [Related]
17. Omalizumab therapy: patients who achieve greatest benefit for their asthma experience greatest benefit for rhinitis.
Humbert M; Boulet LP; Niven RM; Panahloo Z; Blogg M; Ayre G
Allergy; 2009 Jan; 64(1):81-4. PubMed ID: 19076535
[TBL] [Abstract][Full Text] [Related]
18. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma.
Kopp MV; Hamelmann E; Zielen S; Kamin W; Bergmann KC; Sieder C; Stenglein S; Seyfried S; Wahn U;
Clin Exp Allergy; 2009 Feb; 39(2):271-9. PubMed ID: 19016798
[TBL] [Abstract][Full Text] [Related]
19. Omalizumab in the treatment of severe asthma: efficacy and current problems.
Pelaia G; Renda T; Romeo P; Busceti MT; Maselli R
Ther Adv Respir Dis; 2008 Dec; 2(6):409-21. PubMed ID: 19124386
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.
Holgate ST; Chuchalin AG; Hébert J; Lötvall J; Persson GB; Chung KF; Bousquet J; Kerstjens HA; Fox H; Thirlwell J; Cioppa GD;
Clin Exp Allergy; 2004 Apr; 34(4):632-8. PubMed ID: 15080818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
